{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:40:45Z","timestamp":1773243645601,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"DOI":"10.7759\/cureus.105002","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:13:39Z","timestamp":1773173619000},"source":"Crossref","is-referenced-by-count":0,"title":["BRCA1\/2 and CHEK2 Pathogenic Variants in Urological Cancers: A Portuguese Single-Center Experience"],"prefix":"10.7759","author":[{"given":"Margarida","family":"Quinto Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Is\u00e1lia","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Fragoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sid\u00f3nia","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li S","year":"2022","unstructured":"Li S, Silvestri V, Leslie G, et al.. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022, 40:1529-41. 10.1200\/JCO.21.02112","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4098-y","article-title":"Male BRCA mutation carriers: clinical characteristics and cancer spectrum","volume":"18","author":"Ibrahim M","year":"2018","unstructured":"Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. 2018, 18:179. 10.1186\/s12885-018-4098-y","journal-title":"BMC Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225697","article-title":"Pathogenic BRCA variants as biomarkers for risk in prostate cancer","volume":"13","author":"McNevin CS","year":"2021","unstructured":"McNevin CS, Cadoo K, Baird AM, Murchan P, Sheils O, McDermott R, Finn S. Pathogenic BRCA variants as biomarkers for risk in prostate cancer. Cancers (Basel). 2021, 13:5697. 10.3390\/cancers13225697","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2016.0125","article-title":"Urological cancer related to familial syndromes","volume":"43","author":"Costa WH","year":"2017","unstructured":"Costa WH, Jabboure G Netto, Cunha IW. Urological cancer related to familial syndromes. Int Braz J Urol. 2017, 43:192-201. 10.1590\/S1677-5538.IBJU.2016.0125","journal-title":"Int Braz J Urol"},{"key":"ref5","article-title":"Prostate cancer genetic testing: NCCN familial high-risk assessment: breast\/ovarian","volume":"26","author":"Daly MB","year":"2019","unstructured":"Daly MB. Prostate cancer genetic testing: NCCN familial high-risk assessment: breast\/ovarian. Can J Urol. 2019, 26:29-30.","journal-title":"Can J Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24918","article-title":"Germline testing for prostate cancer patients: evidence-based evaluation of genes recommended by NCCN guidelines","volume":"85","author":"Xu J","year":"2025","unstructured":"Xu J, Lu J, Gielzak M, et al.. Germline testing for prostate cancer patients: evidence-based evaluation of genes recommended by NCCN guidelines. Prostate. 2025, 85:1087-95. 10.1002\/pros.24918","journal-title":"Prostate"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi K","year":"2025","unstructured":"Fizazi K, Azad AA, Matsubara N, et al.. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025, 406:461-74. 10.1016\/S0140-6736(25)00683-X","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain M","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, et al.. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020, 383:2345-57. 10.1056\/NEJMoa2022485","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00014","article-title":"DNA-damaging therapies in patients with prostate cancer and pathogenic alterations in homologous recombination repair genes","volume":"8","author":"Graham LS","year":"2024","unstructured":"Graham LS, Henderson NC, Kellezi O, et al.. DNA-damaging therapies in patients with prostate cancer and pathogenic alterations in homologous recombination repair genes. JCO Precis Oncol. 2024, 8:e2400014. 10.1200\/PO.24.00014","journal-title":"JCO Precis Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page EC","year":"2019","unstructured":"Page EC, Bancroft EK, Brook MN, et al.. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019, 76:831-42. 10.1016\/j.eururo.2019.08.019","journal-title":"Eur Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg T","year":"2020","unstructured":"Nyberg T, Frost D, Barrowdale D, et al.. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020, 77:24-35. 10.1016\/j.eururo.2019.08.025","journal-title":"Eur Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.418","article-title":"Germline alterations in cancer susceptibility genes in women with high-risk bladder cancer: implications for germline testing and clinical management","volume":"39","author":"Truong H","year":"2021","unstructured":"Truong H, Sheikh R, Khurram A, et al.. Germline alterations in cancer susceptibility genes in women with high-risk bladder cancer: implications for germline testing and clinical management. J Clin Oncol. 2021, 39:418. 10.1200\/JCO.2021.39.6_suppl.418","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/srep33542","article-title":"Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers","volume":"6","author":"Ge Y","year":"2016","unstructured":"Ge Y, Wang Y, Shao W, et al.. Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers. Sci Rep. 2016, 6:33542. 10.1038\/srep33542","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030710","article-title":"Cancer genetics and therapeutic opportunities in urologic practice","volume":"12","author":"Adashek JJ","year":"2020","unstructured":"Adashek JJ, Leonard A, Roszik J, Menta AK, Genovese G, Subbiah V, Msaouel P. Cancer genetics and therapeutic opportunities in urologic practice. Cancers (Basel). 2020, 12:710. 10.3390\/cancers12030710","journal-title":"Cancers (Basel)"},{"key":"ref15","article-title":"CHEK2-related cancer predisposition","author":"Hanson H","year":"2025","unstructured":"Hanson H, Pal T, Tischkowitz M, et al.. CHEK2-related cancer predisposition. GeneReviews\u00ae [Internet]. Adam MP, Bick S, Mirzaa GM, et al. (ed): University of Washington, Seattle, Seattle (WA); 2025."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.49730","article-title":"Genomic ascertainment of CHEK2-related cancer predisposition","volume":"8","author":"Kim SY","year":"2025","unstructured":"Kim SY, Kim J, Ramos M, et al.. Genomic ascertainment of CHEK2-related cancer predisposition. JAMA Netw Open. 2025, 8:e2549730. 10.1001\/jamanetworkopen.2025.49730","journal-title":"JAMA Netw Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23099","article-title":"Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer","volume":"122","author":"Z\u0142owocka E","year":"2008","unstructured":"Z\u0142owocka E, Cybulski C, G\u00f3rski B, et al.. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer. Int J Cancer. 2008, 122:583-6. 10.1002\/ijc.23099","journal-title":"Int J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson H","year":"2023","unstructured":"Hanson H, Astiazaran-Symonds E, Amendola LM, et al.. Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023, 25:100870. 10.1016\/j.gim.2023.100870","journal-title":"Genet Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma","volume":"29","author":"Epstein JI","year":"2005","unstructured":"Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005, 29:1228-42. 10.1097\/01.pas.0000173646.99337.b1","journal-title":"Am J Surg Pathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34671","article-title":"Age at diagnosis for lung, colon, breast and prostate cancers: an international comparative study","volume":"154","author":"Zahed H","year":"2024","unstructured":"Zahed H, Feng X, Sheikh M, et al.. Age at diagnosis for lung, colon, breast and prostate cancers: an international comparative study. Int J Cancer. 2024, 154:28-40. 10.1002\/ijc.34671","journal-title":"Int J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23204","article-title":"Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers","volume":"76","author":"Gleicher S","year":"2016","unstructured":"Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S. Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers. Prostate. 2016, 76:1135-45. 10.1002\/pros.23204","journal-title":"Prostate"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1840","article-title":"Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness","volume":"80","author":"Patel VL","year":"2020","unstructured":"Patel VL, Busch EL, Friebel TM, et al.. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness. Cancer Res. 2020, 80:624-38. 10.1158\/0008-5472.CAN-19-1840","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.05.005","article-title":"Prostate cancer risk by BRCA2 genomic regions","volume":"78","author":"Nyberg T","year":"2020","unstructured":"Nyberg T, Frost D, Barrowdale D, et al.. Prostate cancer risk by BRCA2 genomic regions. Eur Urol. 2020, 78:494-7. 10.1016\/j.eururo.2020.05.005","journal-title":"Eur Urol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.534","article-title":"BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes","volume":"36","author":"Olmos D","year":"2025","unstructured":"Olmos D, Lorente D, Jambrina A, et al.. BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes. Ann Oncol. 2025, 36:1190-202. 10.1016\/j.annonc.2025.05.534","journal-title":"Ann Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina L","year":"2022","unstructured":"Bukavina L, Bensalah K, Bray F, et al.. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022, 82:529-42. 10.1016\/j.eururo.2022.08.019","journal-title":"Eur Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2024.02.002","article-title":"RENO study: clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain","volume":"51","author":"Badiola LB","year":"2024","unstructured":"Badiola LB, Milagro NL, Lav\u00edn DC, et al.. RENO study: clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain. Semin Oncol. 2024, 51:77-86. 10.1053\/j.seminoncol.2024.02.002","journal-title":"Semin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100063","article-title":"EBANO study: real-world data from patients with locally advanced\/metastatic urothelial carcinoma (la\/mUC) in Northern Spain","volume":"6","author":"Fern\u00e1ndez Rodr\u00edguez R","year":"2024","unstructured":"Fern\u00e1ndez Rodr\u00edguez R, Sagastibeltza N, Pujol Obis E, et al.. EBANO study: real-world data from patients with locally advanced\/metastatic urothelial carcinoma (la\/mUC) in Northern Spain. ESMO Real World Data Digit Oncol. 2024, 6:100063. 10.1016\/j.esmorw.2024.100063","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"ref28","article-title":"CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Wang Y","year":"2015","unstructured":"Wang Y, Dai B, Ye D. CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015, 8:15708-15.","journal-title":"Int J Clin Exp Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4071","article-title":"Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical care-checking CHEK2","volume":"8","author":"Bychkovsky BL","year":"2022","unstructured":"Bychkovsky BL, Agaoglu NB, Horton C, et al.. Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical care-checking CHEK2. JAMA Oncol. 2022, 8:1598-606. 10.1001\/jamaoncol.2022.4071","journal-title":"JAMA Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-020-00190-5","article-title":"Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue","volume":"20","author":"Ni VI","year":"2021","unstructured":"Ni VI, Ivantsov AO, Kotkova MA, et al.. Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue. Fam Cancer. 2021, 20:49-53. 10.1007\/s10689-020-00190-5","journal-title":"Fam Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/464648-brca12-and-chek2-pathogenic-variants-in-urological-cancers-a-portuguese-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:13:40Z","timestamp":1773173620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/464648-brca12-and-chek2-pathogenic-variants-in-urological-cancers-a-portuguese-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.105002","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}